Why did Johnson & Johnson (NYSE:JNJ) secure United States FDA approval for this platform?

Johnson & Johnson (NYSE:JNJ) obtained the regulatory approval to market its Dual Energy THERMOCOOL SMARTTOUCH SF Platform to treat heart rhythm disorders. The technology allows medical practitioners to deploy multiple energy wavelengths through one piece of hardware to improve procedure flexibility.

What specific forms of medical energy can electrophysiologists deliver using the new catheter?

The surgical system allows clinical operators to deliver both traditional thermal radiofrequency energy and alternative, non-thermal pulsed field energy. This dual capability gives surgeons the versatility to choose their ablation method based on case complexity and real-time patient tissue substrates.

How does this newly cleared device coordinate with existing mapping infrastructure inside hospital labs?

The platform is fully integrated into the proprietary CARTO ecosystem to supply advanced real-time digital cardiac mapping and diagnostic visualization. The setup features automated indicator guidance to ensure surgeons apply precise physical contact force against target zones.

What is the historical track record of the underlying catheter technology utilized by Johnson & Johnson (NYSE:JNJ)?

The newly updated dual-energy device is built upon the established structural foundations of the core THERMOCOOL SMARTTOUCH SF product family. This underlying platform carries extensive clinical validation data and has successfully treated more than one million heart patients within the United States.

When will medical centers in the United States gain active commercial access to the device?

The healthcare enterprise intends to commence the first formal clinical procedures utilizing the integrated platform during the summer season. The corporate launch strategy will roll out through a structured, phased commercial distribution program across major domestic surgical centers.

Image for illustrative purposes only. Not a real photo.

Johnson & Johnson secures FDA approval for dual energy catheter

Written by Liezl GambePublished Jul 8, 2026, 11:58 AM

Johnson & Johnson secured United States FDA approval for its Dual Energy THERMOCOOL SMARTTOUCH SF ablation platform.
The system integrates dual energy capabilities, allowing electrophysiologists to toggle between radiofrequency and pulsed field power.
The medical technology advance builds upon existing electronic hardware that has treated over one million domestic patients.

Johnson & Johnson (NYSE:JNJ) secured United States FDA approval for its Dual Energy THERMOCOOL SMARTTOUCH SF Platform to treat increasingly complex cardiac cases using a single integrated catheter.

The newly cleared healthcare device allows specialist electrophysiologists to seamlessly deliver both localized radiofrequency and modern pulsed field energy depending on unique patient anatomy.

“The FDA approval of the Dual Energy THERMOCOOL SMARTTOUCH SF Platform is another important milestone in what has been an incredible pace of innovation for our business,” said Johnson & Johnson MedTech Company Group Chair Michael Bodner.

The technical array coordinates directly with the proprietary CARTO mapping infrastructure to supply real-time indexing guidance and track contact force metrics during delicate surgical procedures.

Following the announcement, Johnson & Johnson's share price was up at $267.24.

The consumer healthcare conglomerate intends to initiate a localized, phased commercial rollout across domestic markets during the upcoming summer months.

The product integration expands on standard hardware baselines that have collectively successfully managed therapy routines for more than one million cardiac patients in America.

Johnson & Johnson secures FDA approval for dual energy catheter

Frequently asked questions

Assets related to this article